Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,190,219
  • Shares Outstanding, K 46,276
  • Annual Sales, $ 700,970 K
  • Annual Income, $ -99,560 K
  • EBIT $ 147 M
  • EBITDA $ 229 M
  • 60-Month Beta 0.71
  • Price/Sales 1.72
  • Price/Cash Flow 5.84
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 61.04% ( -4.12%)
  • Historical Volatility 59.06%
  • IV Percentile 46%
  • IV Rank 18.22%
  • IV High 197.17% on 07/15/24
  • IV Low 30.72% on 06/17/24
  • Put/Call Vol Ratio 1.00
  • Today's Volume 8
  • Volume Avg (30-Day) 63
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 4,022
  • Open Int (30-Day) 4,145

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 0.37
  • Number of Estimates 5
  • High Estimate 0.56
  • Low Estimate 0.27
  • Prior Year 0.42
  • Growth Rate Est. (year over year) -11.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.79 +18.04%
on 04/07/25
27.64 -6.95%
on 04/08/25
+1.18 (+4.81%)
since 03/25/25
3-Month
21.79 +18.04%
on 04/07/25
27.64 -6.95%
on 04/08/25
+1.20 (+4.89%)
since 01/24/25
52-Week
11.16 +130.38%
on 08/13/24
31.67 -18.79%
on 05/17/24
+0.22 (+0.86%)
since 04/25/24

Most Recent Stories

More News
Pacira BioSciences to Present 104-Week Efficacy Data Following a Single Local Administration of PCRX-201 for Patients with Mild to Severe Osteoarthritis of the Knee

PCRX : 25.72 (-1.08%)
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders

PCRX : 25.72 (-1.08%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRX : 25.72 (-1.08%)
Pacira Biosciences Stock Rises On Patent Litigation Settlement: Retail Sentiment Soars

RBC Capital opined that Pacira's settlement of litigation for generic Exparel, which provides some closure to over a year's worth of overhang and uncertainty for shares, is a win for the company and the...

IJR : 99.84 (-0.04%)
VTI : 270.64 (+0.61%)
PCRX : 25.72 (-1.08%)
Pacira Biosciences Stock Surges After-Hours On Exparel Patent Settlement: Retail Investors Rejoice

As part of the deal, Fresenius is barred from marketing a generic version of Exparel until early 2030.

PCRX : 25.72 (-1.08%)
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL

PCRX : 25.72 (-1.08%)
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

PCRX : 25.72 (-1.08%)
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

PCRX : 25.72 (-1.08%)
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual

PCRX : 25.72 (-1.08%)
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PCRX : 25.72 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers. These products are developed using the company's proprietary DepoFoam drug...

See More

Key Turning Points

3rd Resistance Point 26.99
2nd Resistance Point 26.56
1st Resistance Point 26.14
Last Price 25.72
1st Support Level 25.28
2nd Support Level 24.85
3rd Support Level 24.43

See More

52-Week High 31.67
Last Price 25.72
Fibonacci 61.8% 23.84
Fibonacci 50% 21.42
Fibonacci 38.2% 19.00
52-Week Low 11.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar